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ABSTRACT
Promoter hypermethylation and heterochroma-
tinization is a frequent event leading to gene inacti-
vation and tumorigenesis. At the molecular level,
inactivation of tumor suppressor genes in cancer
has many similarities to the inactive X chromosome
in female cells and is defined and maintained by
DNA methylation and characteristic histone modifi-
cations. In addition, the inactive-X is marked by the
histone macroH2A, a variant of H2A with a large
non-histone region of unknown function. Studying
tumor suppressor genes (TSGs) silenced in cancer
cell lines, we find that when active, these promoters
are associated with H2A.Z but become enriched
for macroH2A1 once silenced. Knockdown of
macroH2A1 was not sufficient for reactivation of
silenced genes. However, when combined with
DNA demethylation, macroH2A1 deficiency signifi-
cantly enhanced reactivation of the tumor suppres-
sor genes p16, MLH1 and Timp3 and inhibited cell
proliferation. Our findings link macroH2A1 to het-
erochromatin of epigenetically silenced cancer
genes and indicate synergism between macroH2A1
and DNA methylation in maintenance of the silenced
state.
INTRODUCTION
Abnormal epigenetic silencing of gene transcription is
recognized as a frequent event in many types of cancer.
Similar to mutation, epigenetic silencing causes gene loss
of function, thereby contributing to tumorigenesis (1,2).
Although little is known about the events leading to
silencing, the molecular features of chromatin associated
with the silenced promoters are well characterized (3).
There is considerable similarity between heterochromatin
of epigenetically inactivated genes in cancer, and that
of genes residing on the inactive X chromosome (4).
Both are characterized by DNA methylation of CpG
islands at promoter regions and by histone H3 and H4
deacetylation (5–9). Indeed, DNA demethylating agents
and histone deacetylase inhibitors are effective in
reactivating transcription from such loci (10,11). Both
the inactive X and silenced tumor suppressor genes
(TSGs) in cancer cells are characterized by histone H3
lysine 9 dimethylation (H3K9me2) and HP1 enrichment
(12–14). Another prominent feature of the inactive X is
enrichment for polycomb complex proteins and for
H3K27 trimethylation (15–17). These marks are often
associated with silenced loci in cancer and have been
proposed to precede, and possibly direct, DNA methyla-
tion (18–20).
Another, less-studied, characteristic of the inactive X
chromosome is enrichment for the histone variant
macroH2A. MacroH2A was originally reported to associ-
ate with the inactive X, based on immunoﬂuorescence ex-
periments (21). This association was later conﬁrmed by
chromatin immunoprecipitation (ChIP) experiments that
revealed speciﬁc enrichment for macroH2A on the inactive
X of female cells (22–24). There are three isoforms of
macroH2A encoded by two genes, with one gene coding
for two splice variants: macroH2A1.1 and 1.2 (25–27).
Mice lacking the macroH2A1 variants develop normally
but display some alteration in gene expression in adult-
hood (28,29). The fact that macroH2A1 KO female mice
are fully viable suggests that the protein is not essential for
establishment of the inactive state (28). However, a role
for macroH2A in maintenance of the inactive X was
demonstrated when depletion of macroH2A1 from cells
was found to augment reactivation of a silenced reporter
residing on the inactive X, following application of
DNA demethylating drugs and histone deacetylase inhibi-
tors (30).
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Genome-wide proﬁling of macroH2A distribution demon-
strates that macroH2A is associated primarily with tran-
scriptionally repressed regions and that loss of macroH2A
modulates gene expression during differentiation (31,32).
Other reports suggest a role for macroH2A in regulation
of transcription of dynamic/inducible genes, such as
heat-shock response (33), response to viral infection (34),
PARP1-mediated transcription (35) and transcription
requiring adenosine triphosphate (ATP)-dependent chro-
matin remodeling (36). The large non-histone portion at
the C-terminus of the protein is comprised of a hinge
domain and a macro domain for which the crystallograph-
ic structure has been determined. Macro-domains are
present in many proteins and can bind ADP-ribose or
related molecules (37); nonetheless, this ability is
conserved only in the less abundant macroH2A1.1
isoform.
Two recent studies link macroH2A1 to cancer. In a
computational analysis of gene expression in murine and
human tumors, expression of macroH2A1 was included in
a small gene expression signature which correlated with
the ability of c-Myc to maintain tumorigenesis (38).
Studying macroH2A1 isoforms in a panel of lung cancer
samples (39), macroH2A1.1 levels were found to be
elevated in quiescent cells and decreased in proliferating
cells. Reduced levels of macroH2A1.1 correlated with high
proliferative index and increased risk of recurrence. The
functional signiﬁcance of these observations is currently
unknown. Here, we report that macroH2A1 is associated
with silenced TSG promoters and takes part in maintain-
ing the silent state of such genes.
MATERIALS AND METHODS
Cell lines
HCT116 cells were cultured in McCoy’s 5A medium,
SW480 in RPMI medium, Tert-immortalized WI-38 cells
in MEM medium and RKO in DMEM. All media were
supplemented with 10% fetal calf serum (FCS), penicillin
(50mg/ml), streptomycin (50mg/ml) and 2mM
(L-Glutamine). In addition, WI-38 medium contained
0.1nM NEAA. 5-aza-dC (Sigma) was applied for 6 days
to concentrations of 50–1000nM.
Antibodies and western blot analysis
Anti-macroH2A1 is described in ref. (40). Anti-
MacroH2A2 was kindly provided by A. Ladurner
(EMBL); anti-b-actin: Abcam (ab6276); anti-p16: Santa
Cruz (sc-468). Acetylated H3K9,K14 (Millipore 06-599),
H2A.Z (Millipore 07-594). Secondary antibodies coupled
to horseradish peroxidase (Jackson Immunoresearch
Laboratories).
ChIP
ChIP assays were performed according to the standard
Upstate protocol (41), using Bioruptor bath sonicator
(Diagenode) to shear DNA to an average size of 500bp.
Chromatin from 1.5 10
6 cells was precleared with 40ml
salmon sperm DNA–protein A–agarose beads (Upstate
Biotechnology) for 30min, followed by an overnight incu-
bation with antibody. Eluted DNA was isolated using
QIAGEN PCR puriﬁcation kit.
For polymerase chain reaction (PCR) analysis, the
bound fraction was compared with a 1:100 dilution of
the input DNA. When different samples were compared,
the bound/input values were normalized according to a
positive control to correct for differences in overall IP
efﬁciency between samples (results before normalization
are shown in Supplementary Figures S7–S9). At least
three biological replicates were performed to conﬁrm
ChIP results.
PCR and real-time PCR
PCR reactions were carried out using Red Load Taq
Mastermix (Larova). Primers are listed in
Supplementary Table S1. Quantitative real-time PCR
(qPCR) assays were carried out on ABI Prism 7900
system using SYBR Green PCR Master Mix (Applied
Bioystems). Efﬁciencies of all primer pairs were greater
than 1.89 per cycle.
SNapShot assay
We adapted the SNapShot procedure (Applied Biosystem)
to identify and quantitate an SNP caused by frameshift
mutation in one allele of the CDKN2A locus in HCT116
cells, taking a similar approach to that described by (42).
Brieﬂy, a PCR product carrying the polymorphic site was
generated using the primers CDKN2A SNaPshot F+R
(Supplementary Table 1). Excess primers and dNTPs
where removed using ExoI/SAP. The puriﬁed fragment
was then used as template for SNaPshot with the primer
CDKN2A SNaPshot (this primer ends one base before the
CDKN2A mutation). Thermocycling: 30 (10s 96 C, 5s
50 C, 30s 60 C) was used for single base extension
reaction and DNA was treated with 1U of CIAP
(Fermentas) to remove unincorporated ddNTPs. ABI
PRISM 3700 DNA Analyzer (Applied Biosystem) was
used for visualization and quantitation was done using
the Genotyper 2.1 software (ABI PRISM).
shRNA lentiviral vectors
Construction of lentiviral vectors pLKO1.puro/hygro
carrying shRNA directed against macroH2A1 was as
described (43). The macroH2A1 target sequence used
was 50-CCAGTTACTTCGTGTCTACAA-30. The
macroH2A2 target sequence used was 50-ACAGCGATA
AAGAAGGAACTT-30. Scrambled sequence was 50-GTT
GCCCCTAGACTTAGAACT-30. Viral particles were
produced in 293T cells as described in 43 and target cells
were exposed to two rounds of infection followed by the
relevant selection (2mg/ml puromycin or 140mg/ml
hygromycin).
RNA isolation and reverse transcription-PCR
RNA was isolated using Tri-Reagent (Sigma) followed
by treatment with 2U of RQ RNase free DNase
Nucleic Acids Research,2011, Vol.39, No. 4 1327(Promega) according to the manufacturer’s instructions.
Reverse transcription (RT) was performed on 1mg
DNase treated RNA using 0.5mg random hexamer
primers in a reaction volume of 20ml according to the
manufacturer (ImpromII
tm RT promega).
Methylation analysis
According to the manufacturer’s instructions, 1.2mg
genomic DNA was bisulﬁte-modiﬁed using EZ DNA
Methylation Kit (Zymo Research). PCR reactions were
performed using Faststart taq DNA polymerase (Roche).
RESULTS
Silencing of p16 (CDKN2A) is accompanied by
enrichment for MacroH2A1
Considering the similarity between the heterochromatin of
the inactive X chromosome and that of epigenetically
silenced TSGs, we hypothesized that macroH2A1 may
also be associated with promoters of TSGs, speciﬁcally
when they are epigenetically silenced. To test this possibil-
ity, we used ChIP to assess macroH2A1 enrichment at
active and silenced promoters of known TSGs.
We used WI-38 human embryonic lung ﬁbroblasts, in
which p16
Ink4a (CDKN2A) was found to undergo epigen-
etic silencing through DNA methylation of its promoter.
Silencing occurs spontaneously during passage of these
cells in culture, while treatment of the non-expressing
cells with 5-aza-dC restores p16 expression (44). We
compared cells from a late passage (p32) in which
CDKN2A is methylated and silenced, to cells from an
early passage (p18) which are unmethylated and express
p16 (Figure 1A). Using ChIP with anti-macroH2A1 we
observed enrichment for macroH2A1 at the CDKN2A
promoter only in the late passage cells that have silenced
the gene (Figure 1B), demonstrating speciﬁc association of
macroH2A1 with the inactive state. To validate the
efﬁcacy of our ChIP assay, we compared enrichment for
macroH2A1 at several non-expressed genes to that of
housekeeping genes. MacroH2A1 levels were signiﬁcantly
elevated in the non-expressed tissue-speciﬁc genes
(Supplementary Figure S1A and B). We also performed
ChIP on macroH2A1-deﬁcient ES cells, as negative
control conﬁrming that the bound fraction is dependent
on macroH2A1 presence (Supplementary Figure 1C).
MacroH2A1 is enriched on the epigenetically silenced,
but not the active allele of p16 (CDKN2A)
To further conﬁrm the speciﬁc association of macroH2A1
with the silent state we took advantage of the unique con-
ﬁguration of the p16(CDKN2A) locus found in the
HCT116 colon cancer cell line, in which one allele is
epigenetically silenced, while the other allele is transcrip-
tionally active, but is non-functional due to a frame-shift
mutation in the ﬁrst exon (45). This combination allows a
comparison between an active and silent allele within the
same ChIP experiment. We used the point mutation (a
single base insertion on the active allele) to discriminate
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Figure 1. Silencing of CDKN2A is accompanied by macroH2A1 en-
richment. (A) Expression and methylation status of CDKN2A in early
passage (p18) and late passage (p32) WI-38 cell: western blot for p16
and b-actin showing loss of expression in p32 cells (left panel).
Methylation of the CDKN2A promoter in p32 cell conﬁrmed by
methylation-speciﬁc PCR (MSP) on bisulﬁte-modiﬁed DNA (right
panel). (B) ChIP with macroH2A1 antibody. The bound/input ratio
for each cell line was calculated using quantitative real-time PCR. To
compare between cell lines, enrichment of the bound fraction was
normalized according to the positive control a-Crystallin, which is
inactive in both cultures (Supplementary Figure S6). An 8.5-fold en-
richment for macroH2A1 at the CDKN2A promoter is observed in p32
cells versus p18 cells. Similar results were observed in three biological
replicates (see also Figure 5). HoxA9 is another positive control and is
not expressed. Aprt and MLH1 are expressed in both samples. The
numbers under the gene names indicate position of the interrogated
region relative to TSS. Error bars represent standard deviation.
(C) ChIP analysis using anti-macroH2A1 or anti-acetylated H3
antibody on HCT116 cells. Input and bound fractions were analyzed
by SNaPshot assay to discriminate between the silenced (wild-type)
allele of CDKN2A (S) and the active mutant allele (A). The ratio
between the two alleles (S/A ratio) was determined based on peak
area using Genotyper 2.1 software (ABI PRISM).
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Following ChIP with an antibody against acetylated
H3, the bound fraction was greatly enriched for the
active allele as expected (Figure 1C). By contrast, the
macroH2A1-enriched fraction contained almost exclu-
sively the epigenetically silenced allele of CDKN2A and
not the mutated, transcriptionally active, allele. In two
repeated ChIP experiments, we consistently observed a
>5-fold enrichment in macroH2A1 on the silenced allele
in the bound fraction. This result strongly supports
speciﬁc association of macroH2A1 with the inactive state.
MacroH2A1 is enriched on epigenetically silenced TSGs
in colon cancer cell lines
To determine whether macroH2A1 enrichment might be a
characteristic of epigenetic silencing in cancer, we
analyzed distribution of macroH2A1 at active and
silenced promoters in colon cancer derived cell lines. We
examined two colon cancer cell lines, RKO and SW480, as
the epigenetic status (expression, DNA methylation and
chromatin modiﬁcations) of many loci has been exten-
sively described in these lines (46,47).
We veriﬁed the epigenetic status of selected loci in these
lines by comparing expression levels in the absence or
presence of the DNA demethylating drug 5-aza-dC and
by sequencing bisulﬁte converted DNA (Supplementary
Figure S3). In agreement with previously published data
(46), p16 was epigenetically silenced in both RKO and
SW480 and was reactivated upon demethylation, while
other genes were silenced in only one of the cell lines
(Figure 2A). We then focused our analysis on CpG
islands of genes that are silenced in one cell line but not
the other. In agreement with our prediction, we always
found higher macroH2A1 levels at the silenced promoters.
For MLH1, TIMP3 and CRBP1, which are silenced in
RKO cells, macroH2A levels were found to be higher
in the RKO cells. This pattern was reversed for
GATA4, which is silenced speciﬁcally in SW480 cells
(Figure 2B).
Knockdown of macroH2A1 contributes to the
re-expression of silenced p16
Next, we asked whether macroH2A1 is functionally im-
portant for silencing. Using a lentiviral vector we
introduced stable shRNA against macroH2A1 into
WI-38 (p32) cells with the silenced p16. Although
macroH2A1 protein was effectively depleted from the
cells (Figure 3A), this had no effect on transcription of
p16 (Figure 3B). However, studying the role of
macroH2A1 in silencing of the inactive X,
Hernandez-Munoz et al. (30) reported that combining
knockdown of macroH2A1 with DNA demethylation
and HDAC inhibitors had a synergistic effect on reactiva-
tion of a silenced reporter gene. We ﬁrst repeated these
experiments and observed a strong synergistic effect in
X-inactivation, even in the absence of HDAC inhibitors
(Supplementary Figure S2). Next, we analyzed p16 expres-
sion in WI-38 (p32) cells that were treated with increasing
concentrations of the DNA demethylating agent
5-aza-dC. We observed signiﬁcantly higher expression
levels of p16 in macroH2A1 knockdown cells compared
with control cells (Figure 3B).
Reactivation of TSGs in RKO colon cancer cell line
following KD of macroH2A1
To determine whether macroH2A1 depletion can promote
reactivation of silenced genes in cancer cells, we knocked
down macroH2A1 in RKO cells (Figure 3A) and
evaluated the reactivation of four silenced genes (MLH1,
TIMP3, CRBP1 and CDKN2A). MacroH2A1 deﬁciency
was not sufﬁcient for reactivation of silenced genes, but
similar to WI-38 cells, combining knockdown of
macroH2A1 with low levels of 5-aza-dC resulted in
enhanced reactivation of p16, MLH1 and TIMP3 as
compared to demethylation alone (Figure 3C). Three
additional biological replicates done at 200nM 5-aza-dC
repeatedly indicated enhanced expression in
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Figure 2. MacroH2A1 is associated with epigenetically silenced TSG in
colon cancer cell lines. (A) Epigenetic status of selected genes in RKO
and SW480 cells was conﬁrmed by assaying for reactivation upon
demethylation. Cells were cultured with 1mM 5-aza-dC for 5 days
and transcription was evaluated by RT–PCR. Genes that were ex-
pressed before treatment were considered active (A). Genes that
became transcribed only upon demethylation were considered to be
epigenetically silenced (S). Results were consistent with previously pub-
lished reports on these cell lines (10,46). (B) Chromatin immunopre-
cipitation using anti-macroH2A1 antibody. Enrichment for
macroH2A1 at promoter regions was measured by real-time PCR
analysis of the bound fraction relative to input. To compare between
RKO and SW480 cells the bound/input values were normalized accord-
ing to the positive control a-Crystallin (CRYAA, which is inactive in
both cultures, Supplementary Figure S6). The numbers under the gene
names indicate position of the interrogated region relative to TSS.
Error bars correspond to standard deviation of the Ct. IP with
no antibody gave very low background signal. Similar results were
observed in three repeated experiments (see also Figure 5).
Nucleic Acids Research,2011, Vol.39, No. 4 1329macroH2A1-deﬁcient cells over controls. 2.54±1.04 (SD)
fold increase for p16, 3.1±1.1 for MLH1 and 2.58±0.23
for TIMP3. Similarly, knockdown of macroH2A1 appears
to enhanced the effect of demethylation in reactivation of
the silenced copy of p16 in HCT116 colon cancer cells
(Figure 3D). Reactivation of CRBP1 in RKO cell was
evident only following treatment with at least 1mM
5-aza-dC and simultaneous knockdown of macroH2A1
did not promote further reactivation (data not shown).
This is consistent with the relatively low level of
macroH2A detected at the CRBP1 promoter in RKO
cells (Figure 2B). The ability of 5-aza-dC to induce
dose-dependent demethylation of the examined loci
was conﬁrmed by bisulﬁte sequencing (Supplementary
Figure S3).
Human cells carry two macroH2A genes (26).
Knockdown of macroH2A2 in RKO cells did not
promote reactivation of silenced genes and did not
enhance the reactivation obtained by DNA
demethylation. Knockdown of both macorH2A1 and
macroH2A2 resulted in the enhancement of reactivation
to a level similar to that of macroH2A1 knockdown alone
(Supplementary Figure S4). RKO cells appear to have
relatively low levels of macroH2A2 (data not shown)
and it does not seem to signiﬁcantly contribute to main-
tenance of silenced state in the loci we examined.
We also measured the effect of macroH2A1 knockdown
on growth of RKO cultures: As shown in Figure 4,
knockdown of macroH2A1 had a mild growth inhibitory
effect even without 5-aza-dC treatment. In the presence of
the drug, macroH2A1 knockdown had a signiﬁcant effect
on growth compared with controls (Figure 4).
In conclusion, we ﬁnd synergism between DNA
demethylation and macroH2A1 deﬁciency in reactivation
of three important TSGs and in inhibiting cell culture
growth.
Inverse relationships between macroH2A1 and H2A.Z
Recent genome-wide mapping studies link the histone
variant H2A.Z to promoter regions of transcriptionally
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Figure 3. KD of macroH2A1 facilitates TSGs reactivation. (A) Western blot showing levels of macroH2A1 in WI-38 (passage 32) and RKO cells
infected with Lentiviral macroH2A1 speciﬁc shRNA (mH2A KD) or scrambled shRNA (SC). (B) Real-time RT-PCR analysis of p16 expression in
WI-38 (passage 32) cells with macroH2A1 KD or scrambled KD following treatment with 5-aza-dC. cDNA was analyzed using real-time PCR and
the p16 expression level was normalized to GAPDH. Graph shows fold change in expression level relative to control (scrambled KD) treated with
50nM 5-aza-dC. KD of macroH2A1 resulted in an 8-fold increase in p16 levels following treatment with 50nM 5-aza-dC. (C) Quantitative real-time
RT-PCR analysis of MLH1, TIMP3 and p16 expression in RKO cells. In three repeated experiments, macroH2A1-deﬁcient cells consistently show
better reactivation following treatment with low concentrations of 5-aza-dC. (D) Western blot analysis of p16 levels in HCT116 colon cancer cell line
carrying macroH2A1 KD or scrambled shRNA. Because HCT116 cells express a mutated transcript for one allele, the analysis was done using
western blot analysis and detects only expression from the silenced allele. p16 expression following treatment with 5-aza-dC is enhanced in
macroH2A1-deﬁcient cells.
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inverse relations between H2A.Z and DNA methylation
(50). We speculated that in silenced loci, H2A.Z might be
replaced by macroH2A1. We therefore examined the oc-
cupancy of H2A.Z at the promoters of active and silenced
TSGs (Figure 5). In marked contrast to macroH2A1,
H2A.Z was consistently enriched at promoters of tran-
scriptionally active genes and was absent in cases where
the same gene was silenced both in WI-38 cells and in the
colon cancer cell lines (Figure 5A and B). In most of the
promoters we studied, the TSS is located within a CpG
island. An exception is the TIMP3 promoter, where the
CpG island is positioned 579–1465bp downstream of the
TSS. Interestingly, we ﬁnd that the switch from H2A.Z in
the active, unmethylated state to macroH2A1 in the
silenced and methylated state is clearly observed in the
CpG island but not in the vicinity of the TSS (Figure 5B).
To further deﬁne the function of H2A.Z and
macroH2A in expression, we examined the presence of
the two variants during reactivation of transcription.
Demethylation with 5-aza-dC did facilitate some gene
expression (Supplementary Figure S5) but macroH2A
and not H2A.Z remained associated with the reactivated
loci (Figure 5C and D). Following knockdown of
MacroH2A1, gene expression was further enhanced
(Supplementary Figure S5) but even under these condi-
tions, H2A.Z levels were not signiﬁcantly elevated
(Figure 5D). This result is consistent with the
genome-wide analysis, which indicates that only highly
expressed promoters are associated with H2A.Z (49). It
also suggests that it is MacroH2A1 presence rather than
the H2A.Z absence that contributes to silencing.
MacroH2A1 and de novo DNA methylation
In cancer, H3K27 methylation was suggested to pre-mark
sites of aberrant methylation (18). During X-inactivation
macroH2A1 enrichment of the inactive-X is observed after
methylation of H3K27 but prior to DNA methylation (4).
We considered the possibility that like in X-inactivation,
macroH2A presence may precede DNA methylation
during silencing of TSGs. Silencing and methylation of
p16 is known to occur during culturing of WI-38 cells
(44). However, we concluded that the gradual silencing
of p16 during culturing of WI-38 cells is the result of a
rare silencing and methylation event in a minor popula-
tion of cells, which, due to the growth advantage of
p16-deﬁcient cells, quickly take over the population. We
were therefore not able to directly determine the order
events using this system.
Using genome-scale DNA methylation analysis we have
recently analyzed methylation status of  27000 CpG sites
and identiﬁed nearly 1000 sites that like p16 (CDKN2A)
becomes methylated in late passage WI-38 lung ﬁbroblasts
(51). To examine if macroH2A presence may precede
DNA methylation in the context of cancer associated
DNA methylation, we took advantage of recently pub-
lished data on macroH2A1 genomic distribution in lung
ﬁbroblasts (52) and determined the frequency of de-novo
methylation as a function of macroH2A1 enrichment. As
shown in Figure 6, we ﬁnd that macroH2A1 enriched
regions show higher propensity to undergo de novo methy-
lation. Importantly, genomic analyses show that
macroH2A1 enrichment often correlates with H3K27
methylation (52,53). It was therefore of interest to
determine whether H3K27 methylation directs both
macroH2A1 association and DNA methylation or
whether macroH2A1 has an independent contribution to
recruitment of aberrant methylation.
To address this question in an indirect way, we took
advantage of available data on H3K27 methylation in
human primary lung ﬁbroblasts and calculated the fre-
quency of aberrant methylation as a function of both
H3K27me3 and macroH2A1. Figure 6b shows that as pre-
viously reported (18), aberrant methylation is higher in
H3K27me3 enriched sites. However, we ﬁnd that for any
given level of H3K27me3 the frequency of aberrant
methylation increases with macroH2A1 levels, supporting
the possibility that macroH2A1 presence may promote
DNA methylation at CpG islands independent of
H3K27 methylation.
DISCUSSION
Several complementary mechanisms are involved in
maintenance of the inactive X (4). The same mechan-
isms were shown to take part in abnormal silencing of
genes in cancer cells (2). Here, we demonstrate that
macroH2A1, an established feature of the inactive X, is
also associated with epigenetically silenced TSGs and
takes part in maintenance of the inactive state. As in the
case of the inactive X (30), we found that macroH2A1
contributes to gene silencing in synergy with DNA
methylation.
Studying the p16(CDKN2A) locus in three different cell
lines, we observed enrichment for macroH2A1 speciﬁcally
when the gene is epigenetically inactivated. In this locus,
the removal of macroH2A1 improved the effectiveness of
DNA demethylation in reactivation of transcription,
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Nucleic Acids Research,2011, Vol.39, No. 4 1331indicating a functional role for macroH2A1 in mainten-
ance of the inactive state. Similarly, we observed speciﬁc
enrichment of macroH2A1 in the silenced state and func-
tional contribution of macroH2A1 to silencing of the
TSGs MLH1 and TIMP3.
Synergism between DNA demethylation and
macroH2A1 deﬁciency is evident also when measuring
cell proliferation. Although this effect is consistent with
the role of p16 as a major regulator of cell proliferation,
there is no evidence that the effect on growth is directly
related to TSG reactivation.
Our results demonstrate that in addition to changes in
DNA methylation and histone modiﬁcations in the
promoter region, aberrant silencing results in a change
in nucleosome composition: While H2A.Z is present in
the active state, it is replaced by macroH2A1 in the
silenced state (Figure 5). We ﬁnd that following
demethylation and macroH2A1 knockdown, transcription
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1332 Nucleic Acids Research, 2011,Vol.39, No. 4can be restored even without H2A.Z association,
indicating that H2A.Z presence is not required for tran-
scription from these promoters and suggesting that the
repressive effect of macroH2A1 is not achieved through
exclusion of H2A.Z. A recent study identiﬁed a special
nucleosome, assembled with H2A.Z and the histone H3
variant H3.3, located at the TSS of highly expressed genes
(49). The study further shows that the association of this
nucleosome with DNA is very loose and that preparative
methods used previously resulted in the loss of these
unstable nucleosomes, and an apparent ‘nucleosome free
region’ (NFR). In contrast to the labile nature of H2A.Z
nucleosomes, in vitro experiments suggest that nucleo-
somes containing macroH2A have stronger afﬁnity to
DNA (54) and are refractory to Pol II transcription initi-
ation and to ATP-dependent chromatin remodeling
(36,55) or reduce the recruitment of SWI/SNF chromatin
remodeling complexes (56).
In silenced TSGs DNA methylation is the major mech-
anism responsible for maintenance of the inactive state.
However, while DNA demethylation using 5-aza-dC
removes critical repressive marks and facilitates reactiva-
tion of transcription, it does not restore a fully euchromat-
ic state: demethylation is often partial (57), histone H3K27
methylation remains higher than in the active state (47)
and H2A.Z is not restored (Figure 5). The contribution of
HDAC inhibitors to reactivation of TSGs is observed only
if preceded by DNA demethylation (10). Similarly, the
repressive effect of macroH2A1 presence is evident only
under these conditions.
The means by which macroH2A1 promotes silencing
are not fully understood. In addition to the mechanisms
proposed above, macroH2A variants were shown to affect
the activity of PARP1 and its association with chromatin
(33,35). Interaction of macroH2A1.2 with the E3 ubiqui-
tin ligase Spop has also been proposed to promote
silencing (30). It will be important to determine which of
these mechanisms is relevant in the case of silenced TSGs
as all these pathways involve enzymes which can serve as
drug targets with potential of enhancing the effects of
DNA demethylating agents.
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